FASENRA (AstraZeneca Pty Ltd)
Product name
FASENRA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
215 working days (255)
Active ingredients
benralizumab
Registration type
NCE/NBE
Indication
FASENRA (solution for injection) is indicated as add-on therapy in patients aged 12 years and over with severe eosinophilic asthma (blood eosinophil count ≥300 cells/µL or ≥150 cells/µL if on oral corticosteroid treatment).